Roy Beck, MD, PhD, is the founder of the Jaeb Center for Health Research.

INHALE-1: Afrezza Safe but Not Superior to Rapid-Acting Analogue in Children, With Roy Beck, MD, PhD

Although it failed to reach the prespecified criteria for HbA1c noninferiority, inhaled technosphere insulin (TI) was proven safe and associated with greater treatment satisfaction than rapid-acting analogue (RAA) insulin in the INHALE-1 study.

These data were presented at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona, Spain, by Roy Beck, MD, PhD, founder of the aeb Center for Health Research and lead investigator on the study. 

 spoke with Beck to discuss the pulmonary safety findings from this phase 3 trial.

“It’s advisable to have pulmonary function tests, and it can be done in the office,” Beck told 

. “Maybe 6 months after they’ve started treatment, and if they’re doing okay, then maybe after another 6 months. And then if they’re okay, maybe once a year, unless someone’s getting symptoms. But we did not identify any risk.”

INHALE-1 was a phase 3, open-label, randomized clinical trial evaluating TI’s efficacy and safety in combination with basal insulin versus RAA - including insulin lispro, insulin glulisine, and insulin aspart in combination with basal insulin – in pediatric patients with 

. The trial included 26 weeks of randomized treatment with either TI or RAA, all patients entered an extension period of TI treatment until week 52.

Patients were eligible for INHALE-1 if they were ≥4 and <18 years old with a clinical diagnosis of T1DM or T2DM and had been using insulin for ≥6 months for T1DM or ≥3 months for T2DM. Additionally, patients were required to have an HbA1c ≥7% and ≤11% and be receiving an average prandial dose of insulin ≥2 units per meal, among other criteria. Patients were excluded if they had a history of recent blood transfusions, asthma, serious complications of diabetes, or respiratory tract infection within 14 days of screening, among other criteria.

Patients were then randomly assigned in a 1:1 ratio to either the TI or RAA group. Randomization was stratified by diabetes subtype, baseline HbA1c (<8.5% or ≥8.5%), and age (4 to <13 years or 13 to <18 years). Both groups continued using basal insulin, typically once daily in the evening with either insulin glargine, insulin degludec, or insulin detemir. The primary outcome was change in HbA1c by 26 weeks, with secondary outcomes including binary HbA1c metrics, CGM metrics, and others. Investigators also examined pulmonary function testing as a safety endpoint.

A total of 313 participants were screened and 230 were randomized to the TI group (n = 117) or the RAA group (n = 113). Mean age was 12.6 years (standard deviation [SD], +/- 3 years). 225 patients presented with T1DM and 5 presented with T2DM. In intent-to-treat analysis, mean baseline HbA1c was 8.22 +/- 0.87 and 8.41 +/- 1.38 at 26 weeks with TI and 8.21 +/- 0.96 and 8.21 +/- 1.1, respectively, with RAA (adjusted difference, 0.18; 95% CI, -0.07 to 0.43; noninferiority 

However, despite not meeting the prespecified criteria for HbA1c noninferiority, only 2 severe hypoglycemic events occurred in the TI group and 1 in the RAA group. Treatment was also shown to be safe without affecting pulmonary function compared with RAA, and the TI group reported greater treatment satisfaction (

 = .004) and had less gain in weight and BMI percentile (

“Both the parents and the children expressed greater satisfaction with treatment based on the specific validated survey that was used, even if they didn’t show a benefit in their glucose levels,” Beck said. “I think, possibly because of fewer injections, there’s a greater treatment satisfaction. We actually have a study that’s ongoing now that’s looking at whether starting pediatric patients newly diagnosed with type 1 diabetes on inhaled insulin rather than injections will benefit their adherence.”

Editors’ Note: Beck reports that his institution has received funding on his behalf from Insulet, Tandem Diabetes Care, Beta Bionics, Abbott, Dexcom, Sequel Med Tech, and others.

Haller MJ, Kanapka L, Monzavi R, et al. INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes. Diabetes Care. 2026;49(1):179-187. 

MannKind Corporation. Afrezza INHALE-1 Study in Pediatrics (INHALE-1). ClinicalTrials.gov Identifier: NCT04974528. Updated May 6, 2025. Accessed April 17, 2026. 

https://clinicaltrials.gov/study/NCT04974528

Videos

Beck discusses the recently presented results of INHALE-1, in which technosphere insulin failed to prove noninferiority to RAA but had no pulmonary effects.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

Howard Trachtman, MD, is an adjunct clinical professor of pediatrics at the University of Michigan.

 focal segmental glomerulosclerosis (FSGS)

 may mark more than the arrival of a new therapy, and could signal a turning point in how drugs are developed and evaluated in the disease.

In an interview with HCPLive, Howard Trachtman, MD, an adjunct clinical professor of pediatrics at the University of Michigan and a DUPLEX study investigator, emphasized that the decision reflects both scientific progress and a shift in regulatory clarity that could accelerate future innovation.

https://www.hcplive.com/view/why-sparsentan-fda-approval-marks-a-turning-point-in-fsgs-with-howard-tratchman-md

Previous Limitations In Therapeutic Options For FSGS

“FSGS has been like a graveyard for drug development. It’s a difficult disease, its outcomes are bad, and there’s been really marginal understanding of the pathophysiology of the disease,” said Trachtman.

Historically, limited understanding of disease mechanisms and a lack of validated endpoints discouraged pharmaceutical investment, particularly as research efforts concentrated on more prevalent conditions such as diabetic kidney disease. As Trachtman noted, despite being relatively uncommon, the overall burden of FSGS remains substantial, with few reliable treatment options available to clinicians.

The approval of sparsentan may begin to change that dynamic, in part because it establishes a clearer regulatory pathway for future therapies.

“The approval was based on an endpoint that really opens the door to engagement with pharmaceutical companies, so that they know they have a measure of efficacy that can be considered by regulators,” he explained.

By anchoring efficacy to proteinuria reduction, the decision provides drug developers with a more predictable framework for clinical trial design. This, Trachtman suggested, could encourage broader investment and accelerate the entry of new therapies into clinical testing.

“As we really accelerate the scientific understanding of the heterogeneity of FSGS, clearly more drugs are going to come to the clinic for testing. And this trial really sets a standard that it can be done.”

Beyond expanding the pipeline, Trachtman pointed to a growing emphasis on better characterizing the disease itself. FSGS is increasingly understood as a heterogeneous condition driven by multiple underlying mechanisms, including genetic, immunologic, and metabolic factors.

According to Trachtman, clinicians need to target the right drug to the right patient with FSGS, knowing that they’re not all the same—they’re subtypes.

This shift toward more precise classification may ultimately enable a more personalized approach to treatment, aligning specific therapies with distinct disease pathways.

At the same time, Trachtman emphasized that continued progress will depend on sustained collaboration across the nephrology community, including clinicians, researchers, patients, and industry stakeholders.

“These are hard diseases to study, and cooperation and collaboration is going to be key to really move the ball forward consistently.”

As post-marketing data collection and longer-term follow-up continue, the full clinical impact of sparsentan remains to be defined. However, its approval may already be influencing the trajectory of research in FSGS—transforming a field once marked by limited progress into one poised for renewed therapeutic development.

Podcasts

Listen to our conversation with Trachtman about sparsentan's recent FDA approval for FSGS.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

New 6-month findings from the RELIEVE-PN study suggest individuals with prurigo nodularis treated with dupilumab (Dupixent) show significant improvements in their levels of itch and nodule clearance.

These new results were highlighted during an 

American Academy of Dermatology (AAD) Annual Meeting

, with trial investigator Sarina Elmariah, MD, PhD, MPH, professor of dermatology at the University of California, San Francisco School of Medicine. Elmariah responded to several questions regarding the RELIEVE-PN study, the results’ significance for prurigo nodularis, and more.

Prurigo nodularis is a serious, chronic inflammatory skin condition known for its persistent itch and isolated pruritic firm papules and nodules.

 The following Q&A summary highlights Elmariah’s responses to 

’s inquiries regarding dupilumab for prurigo nodularis:

 Can you start by giving an overview of the RELIEVE-PN study and what question you were aiming to answer with this analysis?

This is an ongoing, real-world study to evaluate Dupixent in clinical practice for adults with prurigo nodularis using patient-reported surveys. This specific analysis assessed interim outcomes related to itch and nodule clearance after 6 months of Dupixent treatment.

How was the study designed, and what makes this real-world, longitudinal survey approach important for understanding outcomes in patients with prurigo nodularis?

 Adults with prurigo nodularis enrolled in the U.S. Dupixent patient support program were recruited for the study. Patients received surveys at baseline and then at 1, 3 and 6 months following Dupixent initiation. Real-world evidence studies like this provide important additional insights into the impact Dupixent can have in clinical practice and further support its approved use for the treatment of adults with prurigo nodularis.

What were the key findings at the 6-month mark, particularly in terms of itch reduction and nodule clearance?

After 6 months of treatment with Dupixent, a significantly higher proportion of patients had ≤5 nodules and no-to-mild itch compared to baseline, which was consistent across the overall population as well as those who continued Dupixent through 6 months (the majority of patients stayed on Dupixent at 1, 3 and 6 months post Dupixent initiation). These significant reductions in nodules and itch started as early as 1 month after patients started taking Dupixent.

How do you interpret the clinical significance of these improvements for patients living with prurigo nodularis?

These results reinforce the efficacy we’ve already seen with Dupixent, but, importantly, demonstrate, in real-world clinical practice, patients themselves are reporting significant reductions in two key outcomes that are particularly burdensome: itch and nodules.

Looking ahead, how do you see these data influencing clinical practice or shaping future research on dupilumab and PN?

 Dupixent is already approved for the treatment of adults with prurigo nodularis, but these results further support its established efficacy in these patients and demonstrate that patients are feeling the improvements themselves in real-world clinical practice.

The quotes used in this Q&A interview summary were edited for clarity.

Elmariah has served as an advisory board member, consultant, investigator, and/or speaker for Bellus Health, Celldex Therapeutics, Eli Lilly, Galderma, Incyte, New Frontier Bio, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and Trevi Therapeutics.

Elmariah S, et al. Patients with prurigo nodularis treated with dupilumab experience significant improvement in itch and nodule clearance: 6-month results from the RELIEVE-PN study. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Cao P, Xu W, Jiang S, Zhang L. Dupilumab for the treatment of prurigo nodularis: A systematic review. Front Immunol. 2023 Jan 20;14:1092685. doi: 10.3389/fimmu.2023.1092685. PMID: 36742321; PMCID: PMC9895771.

Articles

Six-month interim real-world data from RELIEVE-PN indicate that adults with prurigo nodularis treated with dupilumab experienced significant improvements in two high-burden domains: pruritus intensity and nodule burden. Participants were recruited through a U.S. patient support program and followed longitudinally via patient-reported surveys at baseline, 1, 3, and 6 months. Improvements were evident as early as 1 month and were maintained through 6 months, including among those remaining on therapy.

In a Q&A from AAD 2026, Elmariah highlights a variety of significant results highlighted in a poser session from the RELIEVE-PN study regarding dupilumab for prurigo nodularis.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

RELIEVE-PN: Prurigo Nodularis Improves Over 6 Months on Dupilumab, With Sarina Elmariah, MD, PhD, MPH

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include the US Food and Drug Administration (FDA) approval of sparsentan (Filspari) for the treatment of 

focal segmental glomerulosclerosis (FSGS)

, positive topline phase 2 data for SPY001 in 

, the FDA acceptance of a supplemental New Drug Application (sNDA) for delgocitinib (Anzupgo) cream for the treatment of moderate-to-severe chronic hand eczema in adolescents aged 12 to 17 years, the discontinuation of Insmed Incorporated’s brensocatib development program in 

, and the tentative FDA approval of a generic semaglutide injection submitted by Apotex Corp.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of April 12, 2026—let’s jump in!

FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis

On April 13, 2026, the FDA granted full approval to Travere Therapeutics’ sparsentan (Filspari) for the treatment of FSGS, supported by data from 2 of the largest head-to-head interventional studies in adult and pediatric patients with FSGS, the phase 3 DUPLEX study and the phase 2 DUET study. The decision makes sparsentan the first and only drug approved for this indication.

SPY001, An Anti-α4β7, Shows Promise in Phase 2 SKYLINE Trial for Ulcerative Colitis

On April 13, 2026, Spyre Therapeutics announced positive 12-week induction data from Part A of the phase 2 SKYLINE trial of SPY001, a potential best-in-class anti-α4β7 being investigated for the treatment of moderate-to-severely active UC. The Company additionally announced that recruitment for Part A of SKYLINE is now closed and enrollment is open for Part B, which includes 3 monotherapy cohorts (SPY001, SPY002, and SPY003) and 3 combination cohorts (SPY120, SPY130, and SPY230) into which participants may be randomized versus a shared placebo. Proof-of-concept induction data for the remaining cohorts of Part A are now expected mid-2026 (SPY002) and Q3 2026 (SPY003), while Part B induction data for all cohorts remain on track for 2027.

FDA Accepts Delgocitinib sNDA for Chronic Hand Eczema in Adolescents Aged 12–17

On April 15, 2026, the FDA accepted an sNDA for delgocitinib (Anzupgo) cream for the treatment of moderate-to-severe chronic hand eczema in adolescents aged 12 to 17 years. The filing acceptance marks the first regulatory review pathway in the United States specifically targeting the pediatric age group for chronic hand eczema and comes less than 1 year after delgocitinib cream became the first therapy to receive FDA approval for chronic hand eczema in adults in July 2025.

Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued

Insmed Incorporated announced that the phase 2b CEDAR study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms. Based on these data, Insmed indicated plans to discontinue its development program of brensocatib in this disease state and to present these data at a future congress.

FDA Gives Tentative Approval of ANDA for Generic Semaglutide Injection

The FDA announced its tentative approval of an Abbreviated New Drug Application (ANDA) for a generic semaglutide injection submitted by Apotex Corp. The decision marks a regulatory step toward potential generic competition in the GLP-1 RA class. However, the approval does not permit immediate marketing but indicates that the application meets FDA standards for quality, safety, and efficacy, pending resolution of patent or exclusivity barriers.

FDA actions and readouts this week spanned nephrology, immunology, dermatology, and metabolic therapeutics. Sparsentan received full approval as the first indicated therapy for focal segmental glomerulosclerosis, supported by phase 3 DUPLEX and phase 2 DUET data. Spyre reported positive induction results for SPY001 in moderate-to-severe ulcerative colitis and moved into monotherapy and combination cohorts. FDA accepted an adolescent sNDA for topical delgocitinib in chronic hand eczema, while Insmed halted brensocatib in hidradenitis suppurativa after a negative phase 2b CEDAR study. Apotex received tentative ANDA approval for generic semaglutide.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 04/12

Reducing COPD Exacerbations With Tozorakimab, With Frank Sciurba, MD

Tozorakimab, an investigational monoclonal antibody targeting the IL-33 pathway has demonstrated statistically significant and clinically meaningful reductions in 

 (COPD) exacerbations in 2 phase 3 trials, with benefit extending across all blood eosinophil counts and all stages of lung function severity, according to an announcement by AstraZeneca on the phase 3 OBERON and TITANIA trials.

spoke with investigator Frank C. Sciurba, MD, about the new findings, who argued that tozorakimab could open a new therapeutic avenue for the majority of COPD patients who remain inadequately served by current biologic options.

Sciurba, tenured professor of medicine and director of the Emphysema COPD Research Center at the University of Pittsburgh School of Medicine, serves as chief investigator of the LUNA program evaluating tozorakimab (AstraZeneca) in COPD.

Both TITANIA and OBERON were randomized, double-blind, placebo-controlled trials with a combined enrollment of 2,306 patients, recruited irrespective of blood eosinophil count, smoking status, or lung function severity stage, all of whom received tozorakimab 300 mg subcutaneously once every 4 weeks or placebo for 52 weeks on top of standard-of-care inhaled maintenance therapy. The primary endpoint in both trials was the annualized rate of moderate-to-severe COPD exacerbations in the primary population of former smokers; key secondary endpoints assessed the overall population of former and current smokers combined. Both studies met their primary and key secondary endpoints, with tozorakimab demonstrating a statistically significant reduction in moderate-to-severe exacerbations versus placebo in the primary population and in the broader overall population. The safety profile was described as generally favorable and consistent with prior tozorakimab experience. Full results will be presented at a forthcoming scientific meeting; no specific effect-size data have yet been disclosed.

Sciurba described tozorakimab's mechanism as mechanistically upstream of every currently approved biologic in COPD. IL-33 is released by the airway epithelium in response to a variety of stimuli — microbial, irritant, and allergic — and upon release, it engages both innate and adaptive immune responses, feeding into the Th2-mediated pathway that drives eosinophilic inflammation as well as the Th1 and Th17 pathways associated with neutrophilic inflammation. Tozorakimab uniquely inhibits both the reduced and oxidised forms of IL-33, potentially disrupting not only the inflammatory cascade but also the cycle of mucus dysfunction that contributes to disease progression in COPD. This positioning upstream of existing therapeutic targets means the drug theoretically modulates pathways that IL-4 receptor antagonists such as dupilumab and IL-5 inhibitors do not reach — in particular the Th1-dominant inflammatory environment that characterizes most COPD patients.

That distinction has direct clinical implications. The currently approved biologics for COPD — dupilumab, which targets the IL-4 receptor α chain and thus blocks IL-4 and IL-13 signaling, and IL-5 inhibitors — are mechanistically specific to the Th2 pathway and are most effective in patients with elevated blood eosinophil counts. Sciurba estimated that Th2-predominant patients represent approximately 30% of the overall COPD population, leaving the majority — those with low eosinophil counts and a Th1- or Th17-dominant inflammatory phenotype — without a targeted biologic option. This group tends to respond poorly to inhaled corticosteroids and, data suggest, may also derive less benefit from systemic steroids during exacerbations. The OBERON and TITANIA finding that tozorakimab reduced exacerbations across all blood eosinophil counts therefore carries particular significance: it raises the possibility that IL-33 blockade may provide benefit regardless of the dominant inflammatory subtype, addressing a population for which no comparable agent currently exists.

Sciurba noted a pharmacological nuance in this context: the Th1 pathway, while contributing to pathological inflammation in COPD when excessively activated, also serves important homeostatic functions in antimicrobial defense, antiviral immunity, and cancer surveillance. Therapeutic strategies that broadly suppress Th1 responses therefore carry theoretical risks that pathway-specific targeting approaches must carefully calibrate. The OBERON and TITANIA safety data, described as favorable, will be scrutinized in this context when full results are disclosed. Additional trials under the LUNA program — including PROSPERO, a long-term extension study enrolling completers from OBERON and TITANIA, and MIRANDA, assessing an alternative dosing regimen — are ongoing, with data expected in the first half of 2026.

“Tozarakimab is a monoclonal against the IL-33 ligand, and it's involved in a lot of the inflammatory pathways that are affected in COPD. It interestingly affects both Th2 pathways as well as Th1 pathways, and that is of great interest in COPD,” Sciurba said.

Sciurba has reported disclosures including AstraZeneca, COPD Foundation, Gala Therapeutics, GlaxoSmithKline, National Institute of Health, Nuvaira, Patient-Centered Outcomes Research Institute, Pulmonx Corporation, Sano, U.S. Department of Defense, University of Pittsburgh, and Verona Pharma.

AstraZeneca. Tozorakimab met primary endpoint in both OBERON and TITANIA phase III trials in patients with COPD. Press release. March 27, 2026. Accessed March 27, 2026. 

https://www.businesswire.com/news/home/20260327464200/en/Tozorakimab-met-primary-endpoint-in-both-OBERON-and-TITANIA-Phase-III-trials-in-patients-with-COPD

Tozorakimab significantly reduced moderate-to-severe exacerbations in COPD regardless of blood eosinophil count.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

At AAD, April W. Armstrong, MD, MPH, discussed recent innovations in the atopic dermatitis treatment space, highlighting long-term safety data and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

What's New in Atopic Dermatitis Management, With April Armstrong, MD, MPH

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Experts discuss how metabolic and hormonal factors in women influence MASLD risk, progression, and potential long-term outcomes.

Hepatology

Polycystic Ovary Syndrome

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

MASLD and Women’s Health: The Roles of PCOS and Pregnancy

Beck discusses a recent analysis of the phase 4 trial comparing TI and degludec against standard treatment, highlighting the need for individualized titration.

INHALE-3 Analysis Supports Need for Increased Technosphere Insulin Doses, With Roy Beck, MD, PhD

Marie-José van Tol, PhD, from the University of Groningen.

Research suggests preventive cognitive therapy reduced relapse risk in recurrent depression by improving positive affect and anhedonia, van Tol explained in an interview.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Preventive Therapy Targeting Positive Affect May Reduce MDD Relapse, With Marie-José van Tol, PhD

Hanna describes the "freedom" patients with sickle cell disease reported after being treated with reni-cel, a one-time edited gene therapy. 

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Strategic Alliance Partnership

One-Time Gene-Editing Therapy Gives Patients “Freedom” From Pain Crisis

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

View slated expert interviews and 7 clinical trials to watch at AACE Annual Meeting 2026.

AACE Annual Meeting 2026 Preview: 7 Trials to Know

Silvia Mariel Ferrucci, MD, is an adjunct professor of dermatology at the University of Milan and the head of the the Allergology Dermatology Service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

In this Q&A interview, Ferrucci highlights key real-world findings from the GLOBOSTAD on the safety and efficacy of dupilumab (Dupixent) in atopic dermatitis.

GLOBOSTAD: 3 Year Efficacy of Dupilumab in Atopic Dermatitis, With Silvia Mariel Ferrucci, MD

Phillip Levy is an Assistant Professor of Emergency Medicine and Assistant Professor of Physiology at Wayne State University and the Assistant Vice President for Research at Wayne State University Department of Emergency Medicine.

Data from a study deploying mobile health units across Detroit, Michigan, found CKD stage ≥3 rates double the national average and increased rates in at-risk subgroups.


Chronic Kidney Disease

This City’s CKD Stage ≥ 3 Incidence is Double The US National Average

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.



Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Understanding Patient Preferences in Psoriasis, With Andrew Blauvelt, MD, MBA

Armstrong highlights several major takeaways from her portion of the AAD 2026 session titled 'IL-23 Innovation: New Data Addressing Plaque Psoriasis.'

Latest News

INHALE-1: Afrezza Safe but Not Superior to Rapid-Acting Analogue in Children, With Roy Beck, MD, PhD

FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

RELIEVE-PN: Prurigo Nodularis Improves Over 6 Months on Dupilumab, With Sarina Elmariah, MD, PhD, MPH

The HCPFive: Top News for Healthcare Providers from the Week of 04/12

Reducing COPD Exacerbations With Tozorakimab, With Frank Sciurba, MD